http://www.seattlegenetics.com http://finance.yahoo.com/q/ks?s=SGEN http://www.form4oracle.com/company?cik=0001060736&ticker=sgen Seattle Genetics, Inc. operates as a biotechnology company developing monoclonal antibody-based therapies for the treatment of cancer, including lymphoma, multiple myeloma, leukemia, and solid tumors. The company has a worldwide collaboration agreement with Genentech, Inc. to develop and commercialize SGN-40, a humanized monoclonal antibody that is in phase I and phase II clinical development for patients with diffuse large B-cell lymphoma and multiple myeloma. It also has three other proprietary programs in ongoing clinical trials: SGN-33, SGN-35, and SGN-30. The company's SGN-33 is in a phase IIb clinical trial for the patients with acute myeloid leukemia or myelodysplastic syndromes; and SGN-30 and SGN-35 are in phase II clinical trails for the treatment of CD30-positive hematologic malignancies, such as Hodgkin's disease and anaplastic large cell lymphoma. In addition, it developed proprietary antibody-drug conjugate (ADC) technology comprising highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. The company's product candidates also include SGN-70, a humanized anti-CD70 monoclonal antibody with potent effector function and intrinsic cell-killing ability; and SGN-75, which consists of an anti-CD70 monoclonal antibody linked to an auristatin derivative using its proprietary ADC technology. Seattle Genetics has license agreements with Bayer, CuraGen, Progenics, MedImmune, and PDL BioPharma to use its proprietary ADC technology with their monoclonal antibodies; and an ADC co-development agreement with Agensys and Celera Genomics. The company was founded in 1997 and is headquartered in Bothell, Washington
.
